活性凝固因子
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 止血の概要overview of hemostasis [show details]
…using a mouse model of arteriolar injury in which accumulation of fluorescently labeled activated clotting factors was imaged in vivo . Fluorescently labeled factors Xa and Va bound to the endothelium outside …
- 2. 血漿分画製剤および組換えDNA産生凝固因子plasma derivatives and recombinant dna produced coagulation factors [show details]
…Mechanisms of clotting factor activation and roles of the factors in the clotting cascade are discussed in detail separately. Two products that contain clotting factors in the activated form are activated prothrombin …
- 3. 直接作用型経口抗凝固剤を投与されている患者における出血のマネージメントmanagement of bleeding in patients receiving direct oral anticoagulants [show details]
…with activated charcoal and/or hemodialysis; and active interventions including administration of an antifibrinolytic agent, clotting factor products (eg, prothrombin complex concentrates, activated prothrombin …
- 4. 静脈血栓症の原因の概要overview of the causes of venous thrombosis [show details]
… affected patients have marked prolongation in the activated partial thromboplastin time (aPTT) but do not exhibit a bleeding diathesis .… are discussed separately Elevated levels of some clotting factors and chemokines,…
- 5. 凝固検査の臨床使用clinical use of coagulation tests [show details]
… and/or aPTT reflects poor sample collection or preparation techniques. However, clotting factors may be increased or activated in vivo, as in malignancy, DIC, or following short-term exercise, resulting in …
English Journal
- Pharmacokinetics and pharmacodynamics of a recombinant fusion protein linking activated coagulation factor VII with human albumin (rVIIa-FP) in patients with congenital FVII deficiency.
- Gorkom BL, Holme PA, Joch C, Rogosch T, Feussner A, McKeand W, Roberts J, van Heerde W.
- Hematology (Amsterdam, Netherlands). 2020 Dec;25(1)17-25.
- Array Array
- PMID 31852380
- ZEA-induced autophagy in TM4 cells was mediated by the release of Ca activates CaMKKβ-AMPK signaling pathway in the endoplasmic reticulum.
- Feng N, Wang B, Cai P, Zheng W, Zou H, Gu J, Yuan Y, Liu X, Liu Z, Bian J.
- Toxicology letters. 2020 May;323()1-9.
- Zearalenone (ZEA) is a prevalent non-steroidal estrogenic mycotoxin produced mainly by Fusarium contamination. Our previous study showed that ZEA induces the autophagy of Sertoli cells (SCs). However, the underlying mechanisms are still unknown. Several studies have indicated that the increasing lev
- PMID 31982503
- [Clinical phenotype and variantal analysis of a pedigree affected with hereditary coagulation factor V deficiency].
- Che F, Huang W, Yang Y, Wang G, Zhang L, Liang R, Zhao J.
- Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics. 2020 Apr;37(4)427-430.
- To explore the molecular basis for a pedigree affected with coagulation factor V (FV) deficiency. Clinical data of the patient and his family members was analyzed. Targeted capture and next-generation sequencing (NGS) and Sanger sequencing were carried out to detect potential variant of the FV gene.
- PMID 32219828
Japanese Journal
- NMTT基を有するセフェム系抗生物質の使用後に発生した血液凝固障害の1例
- 木村 充,亀谷 真実,梶丸 弘幸,園山 裕靖
- 医学検査 68(4), 781-785, 2019
- … PT），活性化部分トロンボプラスチン時間（activated partial thromboplastintime; …
- NAID 130007733939
- High Titer of Acquired Factor V Inhibitor Presenting with a Pseudo-deficiency of Multiple Coagulation Factors
- Nakata Keiichi,Yonemoto Sayoko,Hayashi Daisuke,Fujii Naohiko,Narahara Hiroyuki,Inui Yoshiaki,Kawata Sumio,Ueda Shuji,Matsunaga Hitomi,Mima Fuka,Ueda Hiroki,Yoshioka Aya,Kaneko Sayoko,Maruo Kazushi,Morris Shayne
- Internal Medicine 57(3), 393-397, 2018
- … A high titer of factor V inhibitor presumably led to a marked inhibition of factor V activity in the specific factor-deficient plasma used in coagulation factor activity assays based on either an activated partial thromboplastin time (APTT) or prothrombin time (PT) clotting assay, resulting in false low values of the coagulation activity. …
- NAID 130006329446
- 岡山 卓史,吉田 順一,奥村 幹夫,宮竹 英志,中原 千尋,大谷 和広
- 日本臨床外科学会雑誌 77(9), 2241-2246, 2016
- … 近年報告が増加しているが，まれな疾患である．症例は83歳の女性．上行結腸癌に対して腹腔鏡下右半結腸切除を施行していた．術後は特に問題なく自宅退院していた．術後1カ月以上経過して右上腕血腫，activated partial thromboplastin time（APTT）が延長する凝固系の異常から後天性血友病と診断し，適切な治療により完解へ至った．死亡率が高率であるため，本疾患が疑われる際には，場合により確定診断を待たずに治療 …
- NAID 130005519822
Related Links
- Activated Clotting Time Activated clotting time (ACT) evaluates the function of coagulation factors in the intrinsic coagulation pathway (Factors VIII, IX, XI, and XII) and the common coagulation pathway (Factor V, X, prothrombin, and
- Clotting factors are usually inactive but once there is tissue injury to the wall of the blood vessel, the first factor is activated. This has a cyclical effect with each factor activating the next. The ultimate aim is for these clotting factors
- This is a quick reference for the laboratory test on activated clotting time (ACT; Activated Coagulation Time). Hemodialysis: therapeutic range of 132 to 234 seconds. It can also help guide the use of protamine sulfate needed to
★リンクテーブル★
[★]
- 英
- activated clotting factors
- 関
- 凝固因子
[★]
- 関
- element、elementary、factorial、parameter
[★]
- 関
- activate、activated form、activation、turn on
[★]
- 関
- activated、activation、turn on
[★]
- 関
- clot、coagulate、coagulation、solidification、solidify、hemostasis